%0 Journal Article
%T 肝癌组织中CD68+肿瘤相关巨噬细胞数量与Ki-67蛋白表达及原发性肝癌预后的关系
%A 曾波航
%A 陈利君
%A 陈静琦
%J 肿瘤防治研究
%D 2016
%R 10.3971/j.issn.1000-8578.2016.09.009
%X 摘要 目的 探讨原发性肝癌（HCC）患者肝癌组织中CD68+肿瘤相关巨噬细胞（CD68+ TAM）的数量与增殖指标Ki-67及肝癌预后的关系，寻找评估肝癌预后更可靠的指标。方法 应用免疫组织化学SABC法检测73例HCC组织中CD68+ TAM的分布情况及增殖指标Ki-67蛋白表达，运用化学发光测定法检测血清AFP水平。结果 CD68+ TAM高密度组Ki-67阳性率明显高于低密度组（P=0.0191）。CD68+ TAM数量与HCC患者的年龄、性别无关（P>0.05），而与HCC病理分级有关（P=2.83E-04）。血清AFP水平与HCC患者的年龄、性别、病理分级无关（P>0.05）。CD68+ TAM高密度组的总生存时间显著短于低密度组（P=0.0004）。而AFP高水平组与低水平组比较，总生存时间、Ki-67阳性率差异均无统计学意义（P>0.05）。结论 HCC患者肝癌组织中CD68+ TAM数量与肝癌增殖活性密切相关，是HCC预后的独立危险因素。与AFP相比，CD68+ TAM有望成为评估肝癌预后更可靠的指标
%K Partial Versus Radical Nephrectomy
%K Apatinib Treatment for Primary Liver Cancer with Lung Metastasis: A Case Report
%K Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Metaanalysis
%K Advance of Immune Checkpoint Inhibitors in Therapy of Liver Cancer
%K Relationship of Macrophage Migration Inhibitory Factor Expression with Clinicopathologic Features and Prognosis of Cardiac Carcinoma Patients
%K Advance of Prognostic Markers of Cervical Cancer
%K Metaplastic Carcinoma of Breast with Mesenchymal Differentiation: 28 Cases Report
%U http://www.zlfzyj.com/CN/abstract/abstract8832.shtml